[{"data":1,"prerenderedAt":19},["ShallowReactive",2],{"blog:cosmetic-safety-substantiation-mocra-requirements":3},{"slug":4,"category":5,"locale":6,"localeCodes":7,"metaTitle":8,"metaDescription":9,"ogImage":10,"title":11,"subtitle":12,"contentHtml":13,"takeaways":14},"cosmetic-safety-substantiation-mocra-requirements","cosmetics_compliance","en",[6],"MoCRA Safety Substantiation: FDA Requirements for Cosmetics","Learn the requirements for cosmetic safety substantiation under MoCRA. Discover what documentation the FDA expects and how to ensure your products are compliant.",null,"Cosmetic Safety Substantiation: Meeting the New MoCRA Standards","Beyond the Label: How to Document and Prove Your Product’s Safety Under Section 608.","\u003Cp>Under the Modernization of Cosmetics Regulation Act (MoCRA), the FDA has shifted from a reactive stance to a proactive one regarding product safety. One of the most significant changes is found in \u003Cstrong>Section 608\u003C/strong>, which mandates that every cosmetic product sold in the United States must have \"adequate substantiation of safety.\"\u003C/p>\u003Ch2>What is Adequate Substantiation?\u003C/h2>\u003Cp>The law defines adequate substantiation as tests, studies, research, analyses, or other evidence that is considered among experts qualified by scientific training and experience to be sufficient to support a reasonable certainty that a cosmetic product is safe. Unlike drugs, the FDA does not \"approve\" these safety dossiers before a product hits the market; however, the \u003Cstrong>Responsible Person\u003C/strong> (the manufacturer, packer, or distributor whose name appears on the label) must ensure this evidence exists and is readily available.\u003C/p>\u003Ch2>The Role of the Responsible Person\u003C/h2>\u003Cp>The Responsible Person is legally accountable for ensuring that the safety of each product is verified before it is marketed. This includes:\u003C/p>\u003Cul>\u003Cli>Maintaining records that support the safety of the finished formulation.\u003C/li>\u003Cli>Ensuring that individual ingredients do not pose a risk under intended conditions of use.\u003C/li>\u003Cli>Providing these records to the FDA if a safety concern arises or during a routine facility inspection.\u003C/li>\u003C/ul>\u003Ch2>What Documentation is Required?\u003C/h2>\u003Cp>While the FDA has not yet issued a rigid template for safety dossiers, industry standards and \u003Ca href=\"https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra\" rel=\"noopener noreferrer\">MoCRA guidance\u003C/a> suggest that a robust safety file should include:\u003C/p>\u003Ch3>1. Ingredient Safety Profiles\u003C/h3>\u003Cp>Documentation on the toxicological profile of each ingredient. This can include data from the Cosmetic Ingredient Review (CIR) expert panel or peer-reviewed scientific literature.\u003C/p>\u003Ch3>2. Finished Product Testing\u003C/h3>\u003Cp>Depending on the product type, this may include stability testing, preservative challenge testing (USP <51>), and dermatological assessments such as Human Repeat Insult Patch Tests (HRIPT) to rule out sensitization or irritation.\u003C/p>\u003Ch3>3. Adverse Event Monitoring\u003C/h3>\u003Cp>A history of any reported adverse events can serve as supporting evidence of a product's safety profile in the real world, though it does not replace the need for initial toxicological assessment.\u003C/p>\u003Ch2>Exemptions for Small Businesses\u003C/h2>\u003Cp>MoCRA does provide some relief for \"small businesses\"—typically defined as those with average annual gross sales in the U.S. for the previous 3-year period of less than $1,000,000. However, these exemptions generally apply to facility registration and product listing, \u003Cstrong>not\u003C/strong> to the core safety of the product. Even small brands must ensure their products are safe for consumers and do not contain prohibited substances.\u003C/p>\u003Ch2>Consequences of Non-Compliance\u003C/h2>\u003Cp>If the FDA determines that a product lacks adequate safety substantiation, the product may be considered \u003Cstrong>adulterated\u003C/strong> under the Federal Food, Drug, and Cosmetic Act. This can lead to serious enforcement actions, including mandatory recalls, import alerts, and seizures of existing stock. In the era of MoCRA, \"we didn't know\" is no longer a valid regulatory defense.\u003C/p>\u003Ch2>How FDA Express Can Help\u003C/h2>\u003Cp>Navigating the transition from voluntary safety standards to mandatory federal requirements can be daunting. At \u003Cstrong>FDA Express\u003C/strong>, we provide the tools and expertise to help you manage your MoCRA obligations. From facility registration and product listings to guidance on labeling and safety documentation, our client portal keeps your compliance data organized and accessible. Ensure your brand is protected by securing your regulatory foundation today.\u003C/p>",[15,16,17,18],"Understand the legal definition of 'adequate substantiation' under MoCRA Section 608.","Identify the 'Responsible Person' tasked with maintaining safety records.","Learn which types of data, including clinical tests and literature reviews, satisfy FDA requirements.","Prepare for FDA inspections by organizing your safety dossiers in advance.",1778105761853]